HDAC6 and AL amyloidosis: Although HDAC6 activity does not drive tumour cell proliferation, HDAC6 has been shown to regulate the response to misfolded protein stress and its inhibition has synergistic effects with Bortezomib, which is administered in relapsed multiple myeloma (Kawaguchi et al, 2003; Bali et al, 2005).